Mainz Biomed Launches ColoAlert® Commercially in Switzerland

Mainz Biomed N.V., a molecular genetics diagnostic company, has announced the commercial launch of its ColoAlert® product in Switzerland. This development follows a strategic partnership with labor team w ag, a notable Swiss diagnostic laboratory, enhancing ColoAlert's availability through an established network.

The Swissmedic approval was a crucial step, allowing ColoAlert® distribution within Switzerland. Additionally, the technology transfer to labor team enables sample processing locally, ensuring high-quality diagnostics for Swiss patients.

Moreover, Mainz Biomed continues to progress with its 2,000 patient study, aiming for full enrollment by the end of 2025. The company opted to complete the study without interim analyses, emphasizing a comprehensive final readout.